Latest News
Hygiene Poverty and the Overlooked Toileting Needs of Women
If you had to choose between food and toilet paper, what would you choose? A UK report from In Kind Direct and The Hygiene Bank found that 47% of people experiencing hygiene poverty had gone without toilet roll, making it the most common product people went without....
Latest News
What the Next Generation of GLP-1s Means for Pharmacists and Patients
GLP-1 receptor agonists (GLP-1 RAs) have reshaped the treatment of type 2 diabetes and obesity. But the next phase of GLP-1 therapy, and of incretin-based treatment more broadly, is likely to have implications that extend well beyond the approval of another...
Del-Desiran Next Steps: Will Novartis Continue After HARBOR?
Novartis has not yet said whether it will keep developing del-desiran, its drug for myotonic dystrophy type 1 (DM1). The del-desiran next steps depend on the full HARBOR dataset and on talks with regulators. On 27 October 2026, Novartis reported a USD 1.9 billion...
Interoperability Begins Where Data Exchange Ends
Standards and APIs can move information. True healthcare interoperability requires the governance, trust and workflow design that make the information usable. Healthcare has spent years treating interoperability as a problem of moving data. National exchange has...
Psychobiotics and Depression: Exploring the Gut–Brain Connection
Depression care continues to evolve as researchers explore why people respond differently to treatment. One area drawing attention is the relationship between the gut microbiome and the brain. Could psychobiotics, which target this connection, offer additional support...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Clinical Trial Results | 9 October 2026
The clinical trial results 9 October 2026 span haematological oncology, rare skeletal disease, metabolic medicine, coeliac disease and autoimmunity. The FDA expanded Eli Lilly’s Jaypirca into previously untreated chronic lymphocytic leukaemia. BridgeBio Pharma’s oral...
Food and Medicines: Why the Leaflet and the Label Do Not Match
Why closing the gap between clinical nutrition advice and the food labels in the supermarket aisle is a data problem before it is an education problem. Around 11 million deaths in 2017 were attributable to dietary risk factors, according to the Global Burden of...
Petrelintide in Type 2 Diabetes: How Does It Compare?
Petrelintide in type 2 diabetes cannot yet be ranked against tirzepatide or semaglutide, because the trial designs differ. Zealand Pharma, which develops the drug with Roche, reported Phase 2b ZUPREME-2 topline data on 7 October 2026. Mean weight loss reached up to...
More Data, Smarter AI: Is Life Sciences Making Better Decisions?
The life sciences sector has always depended on the quality of evidence behind its decisions. Today, the volume of evidence, and the speed at which it can be analysed, is changing dramatically with artificial intelligence. In September, the National Commission into...
Newly Diagnosed Glioblastoma Trial Misses Primary Survival Endpoint
MimiVax and Roswell Park Comprehensive Cancer Center reported topline Phase 2b data on 7 October 2026. The SURVIVE trial tested the survivin peptide vaccine SurVaxM in newly diagnosed glioblastoma. The primary endpoint was overall survival. The full study population...
Digital Twins Need a New Validation Trigger: Drift, Not Deployment
A digital twin commissioned to mirror a manufacturing process is, by design, built to keep learning. It ingests live sensor data, recalibrates its internal parameters, and narrows the gap between what it predicts and what the physical process is actually doing. That's...
Pharmacogenomics Has Left the Lab. Now Comes the Hard Part.
In every industry, there is a lag period between breakthrough and implementation, but perhaps none so long as in healthcare, where medical advances such as pharmacogenomics (PGx) might not show up in practices for years or even decades. While there are myriad reasons...
Traditional Botanical Knowledge: A Research Lead, Not a Health Claim
I like to call myself a conduit between ancient healing wisdom and modern life. I came to the US thirty years ago to be trained as a pathologist, but I grew up among generations of herbalists. My family roots and my research background have shaped how I view the...
Digital Validation in Life Sciences: CSA, Annex 11 and Annex 22 in 2026
For most of the past three decades, validating a computerised system in a GMP facility has usually meant paper. Teams compiled binders of test scripts, wet-ink signatures and printed screenshots. That model is now under pressure, and digital validation in life...
The Future of Diagnostics Is Molecularly Precise
The landscape of modern healthcare is increasingly reliant on the speed, accuracy, and accessibility of In Vitro Diagnostics (IVD). From rapid point-of-care infectious disease tests to complex oncology biomarker profiling, IVD assays play a central role in clinical...
EGFR Exon 20 Insertion Trial Misses Its Primary Endpoint
ArriVent BioPharma has reported a miss on the primary endpoint of its pivotal Phase 3 trial. The study enrolled patients with EGFR exon 20 insertion lung cancer. The global FURVENT study tested the oral inhibitor firmonertinib against platinum chemotherapy. All...
Healthcare AI Needs Trusted Evidence and Communication Standards
The resignation of Anthropic researcher Jacob Coxon has brought renewed attention to the risks of increasingly powerful artificial intelligence. According to the Associated Press, Coxon warned that competitive pressure was overtaking safety considerations at leading...
Clinical Trial Results | 9 October 2026
The clinical trial results 9 October 2026 span haematological oncology, rare skeletal disease, metabolic medicine, coeliac disease and autoimmunity. The FDA expanded Eli Lilly’s Jaypirca into previously untreated chronic lymphocytic leukaemia. BridgeBio Pharma’s oral...
Food and Medicines: Why the Leaflet and the Label Do Not Match
Why closing the gap between clinical nutrition advice and the food labels in the supermarket aisle is a data problem before it is an education problem. Around 11 million deaths in 2017 were attributable to dietary risk factors, according to the Global Burden of...
Petrelintide in Type 2 Diabetes: How Does It Compare?
Petrelintide in type 2 diabetes cannot yet be ranked against tirzepatide or semaglutide, because the trial designs differ. Zealand Pharma, which develops the drug with Roche, reported Phase 2b ZUPREME-2 topline data on 7 October 2026. Mean weight loss reached up to...
More Data, Smarter AI: Is Life Sciences Making Better Decisions?
The life sciences sector has always depended on the quality of evidence behind its decisions. Today, the volume of evidence, and the speed at which it can be analysed, is changing dramatically with artificial intelligence. In September, the National Commission into...
Newly Diagnosed Glioblastoma Trial Misses Primary Survival Endpoint
MimiVax and Roswell Park Comprehensive Cancer Center reported topline Phase 2b data on 7 October 2026. The SURVIVE trial tested the survivin peptide vaccine SurVaxM in newly diagnosed glioblastoma. The primary endpoint was overall survival. The full study population...
Digital Twins Need a New Validation Trigger: Drift, Not Deployment
A digital twin commissioned to mirror a manufacturing process is, by design, built to keep learning. It ingests live sensor data, recalibrates its internal parameters, and narrows the gap between what it predicts and what the physical process is actually doing. That's...
Pharmacogenomics Has Left the Lab. Now Comes the Hard Part.
In every industry, there is a lag period between breakthrough and implementation, but perhaps none so long as in healthcare, where medical advances such as pharmacogenomics (PGx) might not show up in practices for years or even decades. While there are myriad reasons...
Traditional Botanical Knowledge: A Research Lead, Not a Health Claim
I like to call myself a conduit between ancient healing wisdom and modern life. I came to the US thirty years ago to be trained as a pathologist, but I grew up among generations of herbalists. My family roots and my research background have shaped how I view the...
Digital Validation in Life Sciences: CSA, Annex 11 and Annex 22 in 2026
For most of the past three decades, validating a computerised system in a GMP facility has usually meant paper. Teams compiled binders of test scripts, wet-ink signatures and printed screenshots. That model is now under pressure, and digital validation in life...
The Future of Diagnostics Is Molecularly Precise
The landscape of modern healthcare is increasingly reliant on the speed, accuracy, and accessibility of In Vitro Diagnostics (IVD). From rapid point-of-care infectious disease tests to complex oncology biomarker profiling, IVD assays play a central role in clinical...
EGFR Exon 20 Insertion Trial Misses Its Primary Endpoint
ArriVent BioPharma has reported a miss on the primary endpoint of its pivotal Phase 3 trial. The study enrolled patients with EGFR exon 20 insertion lung cancer. The global FURVENT study tested the oral inhibitor firmonertinib against platinum chemotherapy. All...
Healthcare AI Needs Trusted Evidence and Communication Standards
The resignation of Anthropic researcher Jacob Coxon has brought renewed attention to the risks of increasingly powerful artificial intelligence. According to the Associated Press, Coxon warned that competitive pressure was overtaking safety considerations at leading...
Featured Articles
Further News
Younger TAVR Patients Raise the Bar for Long-Term Valve Performance
As transcatheter aortic valve replacement (TAVR) expands into younger patients with longer life expectancy, the definition of a successful procedure needs to grow with it. A July 2026 international position statement identified this trend as a reason for greater focus...
Biotech Deal Structure: Upfronts, Milestones and Royalties Explained
On 2 October 2026, Novartis agreed to license an autoimmune candidate from Abogen for $575 million upfront. Abogen’s release said milestones could add up to about $7.2 billion if every option is exercised. Many headlines led with the combined figure of about $7.8...
Lower Drug Prices Mean Little If the Medication Can’t Reach the Resident
The debate over prescription drug costs, in long-term care as elsewhere, often starts and ends with a number. How much did the medication cost before a negotiated price? How much will Medicare pay? What will the patient owe at the pharmacy counter? Those are important...
Pneumococcal Conjugate Vaccine Meets Phase 3 Goals, Two Serotypes Lag
Vaxcyte reported positive topline results from OPUS-1 on Monday 5 October 2026. The pivotal adult Phase 3 tested VAX-31, the company’s 31-valent pneumococcal conjugate vaccine. It is the first of three adult Phase 3 trials to report. The release was datelined San...
Who Confirms the Alert Before Dawn?
I practice emergency medicine. Overnight care is where timing funds or fails any sepsis early warning tool. A recommendation that sits unconfirmed for hours is not decision support. It is wallpaper. Confirmation is the intervention Accuracy slides still dominate...
The Model Said No. Who Gets to Overrule It?
In rare tumors, oncologists know the usual story. PD-L1 is a weak compass. Tumor mutational burden is often unavailable. The evidence base was never built. So when MD Anderson investigators revisited biopsies from 84 patients in a phase 2 basket trial of pembrolizumab...
Weekly News Roundup | 05 October 2026
Life science news 5 October 2026: four US approvals, three deals and two UK regulatory items. The FDA approved Emcitate, which it calls the first treatment for MCT8 deficiency. The FDA approved a heart valve that can be expanded as a child grows. AstraZeneca agreed to...
Novartis Licenses Abogen mRNA-Encoded T-Cell Engager for $575m Upfront
Novartis has licensed an mRNA-encoded T-cell engager from Abogen Biosciences of Suzhou, China. Abogen announced the licensing and option agreement through PR Newswire on Friday 2 October 2026. The upfront payment is 575 million US dollars. Milestones could add up to...
Why Periodontitis Matters Beyond Dentistry
In brief: Periodontitis, the advanced form of gum disease, is consistently linked with cardiovascular disease, type 2 diabetes and adverse pregnancy outcomes. Only the diabetes link is supported by treatment trials, in which periodontal therapy lowers HbA1c by about...
Low FODMAP Diet and Disordered Eating in IBS
A new study published in September has reinforced how, for people with IBS who have been taught the low FODMAP diet, uncontrolled digestive symptoms and psychological distress can be linked to disordered eating behaviours. It can help us think about how patients are...
Clinical Trials Roundup | 2 October 2026
The clinical trial results 2 October 2026 span hepatitis delta, wet macular degeneration, Niemann-Pick disease, COVID-19 and skin cancer. Mirum Pharmaceuticals’ brelovitug met its primary endpoint in chronic hepatitis delta. Kodiak Sciences’ Zenkuda and tabirafusp-ted...
Beyond the Scale: Meaningful Follow-Up in GLP-1 Care
A GLP-1 follow-up appointment can produce a clear number without answering the most important question: how is this person doing? Weight remains relevant in obesity care, but a useful review also creates space for symptoms, everyday function and the practical work of...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.